Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.44 USD
+0.03 (0.68%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $4.44 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Zacks News
Vanda Pharmaceuticals (VNDA) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 7.14% and 166.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst (BCRX) Wins FDA Approval for HAE Drug Orladeyo
by Zacks Equity Research
BioCryst (BCRX) obtains FDA approval for berotralstat for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients.
Rhythm (RYTM) Up on FDA Approval of Weight Management Drug
by Zacks Equity Research
Rhythm's (RYTM) stock gains as FDA approves its lead product candidate for chronic weight management.
Alexion's (ALXN) Ultomiris IV Formulation Gets EC Approval
by Zacks Equity Research
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Roche (RHHBY) Gets FDA Nod for Influenza Drug Label Expansion
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for Xofluza to prevent influenza in people 12 years of age and older following contact with someone with influenza.
Bristol Myers' (BMY) CAR T-Cell Therapy BLA Review Delayed
by Zacks Equity Research
Bristol Myers (BMY) announces a delay in the FDA review of its BLA for lisocabtagene maraleucel due to COVID-19 pandemic.
Roche's (RHHBY) Influenza Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche's (RHHBY) influenza drug Xofluza and Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) get a positive CHMP opinion.
Vanda Pharmaceuticals (VNDA) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 37.50% and -5.77%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Vanda Pharmaceuticals (VNDA) Q2 Earnings Surpass Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 100.00% and -1.26%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FDA Grants Extra Access to Vanda's Tradipitant to a Patient
by Zacks Equity Research
Vanda (VNDA) gets authorization from the FDA for expanded access to tradipitant for a single patient for six more months.
Vanda Pharmaceuticals (VNDA) Meets Q1 Earnings Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 0.00% and 0.81%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Apr 17, 2020
by Zacks Equity Research
Companies in the news are: TSM, BK, LOVE, VNDA
Vanda Begins Enrollment in Study for Severe Coronavirus Infection
by Zacks Equity Research
Vanda (VNDA) and The Feinstein Institutes for Medical Research initiate enrollment in the phase III ODYSSEY study on tradipitant to treat inflammatory lung injury associated with COVID-19 infection.
7 Stocks With Low Price-to-Sales Ratio for a Solid Portfolio
by Zacks Equity Research
A stock with a lower price-to-sales ratio is a more suitable investment than a stock with a high price-to-sales ratio.
Vertex (VRTX) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
Vertex (VRTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Top Ranked Value Stocks to Buy for November 14th
by Zacks Equity Research
Here are three stocks with buy rank and strong value characteristics for investors to consider today, November 14th
Analysts Estimate Vanda Pharmaceuticals (VNDA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Vanda (VNDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study
by Zacks Equity Research
Menlo (MNLO) completes enrollment in the phase II study evaluating the safety and efficacy of once-daily oral serlopitant for the treatment of CPUO.
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
by Zacks Equity Research
Key highlights of the past week include drug approvals, and other regulatory and pipeline news.
Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment
by Zacks Equity Research
Vanda Pharmaceuticals (VNDA) receives a CRL from the FDA for the sNDA of Hetlioz (tasimelteon) to treat Jet Lag Disorder.
Why Vanda (VNDA) Might be Well Poised for a Surge
by Zacks Equity Research
Vanda (VNDA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Vanda Pharmaceuticals (VNDA) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Vanda (VNDA) delivered earnings and revenue surprises of 800.00% and 7.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?